Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB-A445 alone and in combination with tislelizumab.
Epistemonikos ID: fd9c2462a41e983e12ddfba274ec59d8b966531a
First added on: May 06, 2024